What is the written description requirement?
The written description requirement is one of three distinct requirements under 35 U.S.C. § 112(a) — along with enablement and best mode. It requires that the patent specification contain a written description of the invention sufficient to demonstrate that the inventor had possession of the claimed subject matter at the time the patent application was filed. The standard, established by the Federal Circuit in Ariad Pharmaceuticals v. Eli Lilly (2010, en banc), asks whether the specification 'reasonably conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.' Satisfying written description requires more than vague functional language or a general wish list — it requires structural or functional description of the actual claimed subject matter.
Written description vs. enablement: two distinct requirements
Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010) definitively confirmed that written description and enablement are separate, independent requirements under § 112(a). Enablement asks whether the specification teaches a person of ordinary skill in the art how to make and use the full scope of the claimed invention without undue experimentation. Written description asks whether the specification demonstrates that the inventor had possession of the claimed invention as of the filing date — whether the inventor actually knew what they were claiming. A specification can enable something without adequately describing it (a common situation with broad functional claims), and vice versa. Both requirements must be independently satisfied.
The 'possession' standard in practice
Courts apply the written description requirement by asking whether a person skilled in the art would conclude from reading the specification that the inventor had possession of the full scope of the claimed invention. 'Possession' does not require that the inventor physically made or tested every claimed embodiment — it requires that the specification describe those embodiments with sufficient structural or functional specificity that a skilled reader could conclude the inventor knew of and possessed them. For small-molecule pharmaceutical claims, describing a specific compound with defined structural formula typically satisfies written description for that compound. For broad genus claims, describing only one representative species does not demonstrate possession of the full genus.
Genus claims and written description
Genus claims — claims covering a broad class of variants rather than specific examples — face heightened scrutiny under the written description requirement. The Federal Circuit has held that a broad functional claim (e.g., 'an antibody that binds to protein X and inhibits activity Y') fails written description if the specification only discloses one or a few specific antibodies and does not demonstrate possession of the full class of antibodies that could satisfy the functional limitation. This is because the genus is defined by function, not by structure, and a skilled reader cannot determine from the specification whether the inventor actually had possession of all functional variants. Representative species disclosure across the full structural and functional breadth of the genus is needed.
Antibody claims: written description's most litigated frontier
Written description requirements for antibody claims have been the subject of major Federal Circuit decisions following Ariad. The court has repeatedly held that claiming 'an antibody that binds to [antigen]' without disclosing the antibody's structural features (amino acid sequence of at least the CDR regions, or other structural characteristics) fails written description — even if the specification describes the antigen. The rationale: knowing the antigen does not mean the inventor possessed the antibodies. Key cases include Centocor Ortho Biotech v. Abbott Labs (Fed. Cir. 2011, which held Abbott's anti-TNFα antibody claims invalid), and Amgen v. Sanofi (Fed. Cir. 2021 and Supreme Court 2023, where enablement and written description claims for broad antibody genus were both addressed). Disclosing representative sequences and structural features that correlate with the claimed functional properties is essential.
Written description in continuation applications
Written description is most frequently contested in continuation applications, where an applicant adds or amends claims to cover subject matter that was not explicitly discussed in the original specification. The question is whether the original specification as filed provides written description support for the later-claimed subject matter. If a continuation applicant adds claims to cover a competitor's product discovered after the original filing, the claims may lack written description support even though the competitor's product would technically fall within the literal language of the claims — because the inventor did not have possession of that specific embodiment when the application was filed. Courts scrutinize whether later-added claims represent a 'claim expansion' that goes beyond what was originally disclosed.
New matter and written description
A related concept is the prohibition on adding 'new matter' to a patent application (35 U.S.C. § 132). When a patent applicant files amendments during prosecution — adding claim limitations, changing claim language, or adding to the specification — the new content cannot add 'new matter' not present in the original disclosure. The written description requirement provides the substantive test: if the amended claim or specification language has no basis in the original specification (i.e., the original specification does not provide written description support for the new language), it is impermissible new matter. The distinction between clarifying an original disclosure and adding new matter is frequently contested, particularly when applicants try to narrow claims to avoid prior art through claim amendments.
Best practices for written description compliance
To satisfy written description requirements, patent applications should: disclose specific structural embodiments, not just functional results; for chemical and pharmaceutical inventions, provide structural formulas for key compounds and representative analogs; for antibody or biologic claims, disclose structural data (amino acid sequences, structural features) for representative members of any claimed genus; for software and method claims, describe the specific implementations, not just the desired outcome; and when using broad genus language in claims, provide representative species across the full breadth of the claimed genus. The more structurally diverse the claim scope, the more representative disclosure is required. Draft with the realization that claims that outrun the disclosure will be vulnerable to written description challenge in litigation.
Frequently Asked Questions
What is the written description requirement?
The written description requirement under 35 U.S.C. § 112(a) requires that the patent specification contain a written description of the invention that is sufficient to show that the inventor had possession of the claimed invention at the time the application was filed. It is separate from (and in addition to) the enablement requirement. The test, articulated by the Federal Circuit in Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010, en banc), asks whether the specification 'reasonably conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.' Failure to satisfy written description makes a patent claim invalid.
How does written description differ from enablement?
Written description and enablement are two separate requirements under § 112(a), confirmed as distinct by the Federal Circuit in Ariad Pharmaceuticals (2010). Enablement asks whether the specification teaches a person of ordinary skill in the art how to make and use the full scope of the claimed invention without undue experimentation. Written description asks whether the specification demonstrates that the inventor actually possessed the claimed invention at the time of filing — whether the disclosure shows the inventor knew what they were claiming. A claim can fail written description without failing enablement (e.g., the disclosure teaches how to make compounds but doesn't demonstrate the inventor possessed the full claimed genus), and vice versa. Both must be satisfied independently.
What is the written description standard for genus claims?
Genus claims — claims that cover a broad class of compounds or variants (including Markush claims and functional claims) — face heightened written description scrutiny. The Federal Circuit has held that to adequately describe a genus, the specification must disclose representative species across the structural and functional scope of the genus. Simply claiming a broad genus by reciting a function (e.g., 'an antibody that binds to X') without disclosing species that represent the full scope of the genus fails written description. The more structurally diverse the genus, the more representative disclosure is required. For antibody patents, the court has held that disclosing the amino acid sequence of a single antibody does not adequately describe a genus of all antibodies that bind a particular antigen.
What happened in Ariad v. Eli Lilly on written description?
Ariad Pharmaceuticals v. Eli Lilly (Federal Circuit, en banc, 2010) definitively established that written description is a separate requirement from enablement under § 112(a) — a question that had been debated for years in the Federal Circuit. Ariad held patent claims covering 'reducing NF-κB activity' broadly, using functional language that covered an enormous class of potential compounds. The court held that the claims failed written description because the specification disclosed only one approach to reducing NF-κB activity and did not demonstrate possession of the full range of means for achieving the claimed functional result. The decision is foundational for evaluating broad functional claims in pharmaceutical and biotechnology patents.
How does written description apply when filing continuation applications?
Written description is most commonly litigated in the continuation application context. When a patent owner files a continuation and adds new claims, or amends claims to cover a competitor's product that was not described in the original application, the question arises whether the original specification provides written description support for the new or amended claims. The Federal Circuit has held that a continuation claim is only valid if the subject matter of that claim was adequately described in the parent application's specification as filed — the inventor cannot add new matter through a continuation. This is especially important in the pharmaceutical context, where patent owners sometimes attempt to 'capture' competitors' products through continuation claims that were not contemplated when the specification was written.